Joel Ackerman
Insider (Form 4 reporting owner): CFO and Treasurer CIK 1220630Name as filed: ACKERMAN JOELIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 20 Sep 2016, sold $25.9M in 4 sales and bought $37K in 5 open-market purchases across 2 companies.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| DaVita DVA | CFO and Treasurer | 5 Aug 2021 | 7 May 2026 | – | 3$25.5M |
| Champions Oncology CSBR | Director | 20 Sep 2016 | 1 Oct 2018 | 5$37K | 1$384K |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | too few trades2 trades | too few trades2 trades | too few trades2 trades |
| After sales | too few trades4 trades | too few trades4 trades | too few trades3 trades |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 1 | $9.9M | -$9.9M |
| 2024 | – | – | 1 | $10.7M | -$10.7M |
| 2021 | – | – | 1 | $5.0M | -$5.0M |
| 2018 | – | – | 1 | $384K | -$384K |
| 2016 | 5 | $37K | – | – | $37K |
Every trade
9, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 7 May 2026 | DaVita DVA | Sell | 51,471 | $192.10 | $9.9M | No | Form 4filed 11 May 2026 |
| 27 Aug 2024 | DaVita DVA | Sell | 68,769 | $155.06 | $10.7M | No | Form 4filed 29 Aug 2024 |
| 5 Aug 2021 | DaVita DVA | Sell | 37,760 | $131.36 | $5.0M | Not stated | Form 4filed 6 Aug 2021 |
| 1 Oct 2018 | Champions Oncology CSBR | Sell | 22,535 | $17.02 | $384K | Not stated | Form 4filed 3 Oct 2018 |
| 18 Oct 2016 | Champions Oncology CSBR | Buy | 2,000 | $1.70 | $3K | Not stated | Form 4filed 20 Oct 2016 |
| 13 Oct 2016 | Champions Oncology CSBR | Buy | 7,300 | $1.67 | $12K | Not stated | Form 4filed 14 Oct 2016 |
| 6 Oct 2016 | Champions Oncology CSBR | Buy | 8,202 | $1.63 | $13K | Not stated | Form 4filed 7 Oct 2016 |
| 23 Sep 2016 | Champions Oncology CSBR | Buy | 33 | $1.65 | $54.5 | Not stated | Form 4filed 26 Sep 2016 |
| 20 Sep 2016 | Champions Oncology CSBR | Buy | 5,000 | $1.67 | $8K | Not stated | Form 4filed 21 Sep 2016 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.